Skye Bioscience CFO files initial Form 3

Skye Bioscience, Inc. filed an initial Form 3 for Chief Financial Officer John P. Sharp.

Rhea-AI Filing Summary

Skye Bioscience, Inc. filed an initial Form 3 for Chief Financial Officer John P. Sharp. This filing establishes him as a reporting person for the company’s equity securities. The filing shows no reported transactions or holdings in either common stock or derivative securities at this time.

Key Terms

Form 3, Chief Financial Officer, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Financial Officer financial

""officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

reporting person regulatory

"This filing establishes him as a reporting person for the company’s equity securities."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Skye Bioscience (SKYE) Form 3 for John P. Sharp show?

The Form 3 for Skye Bioscience’s CFO John P. Sharp records his status as a reporting person. It does not list any transactions or derivative positions and shows no reported holdings at the time of this initial filing.

Who is the reporting person on the Skye Bioscience (SKYE) Form 3?

The reporting person is John P. Sharp, identified as the Chief Financial Officer of Skye Bioscience, Inc. This establishes his obligation to report future changes in his ownership of the company’s equity securities.

Does the Skye Bioscience (SKYE) Form 3 include any stock transactions?

The Form 3 includes no stock transactions. The transaction summary shows zero buys, zero sells, zero exercises, and no gifts or tax withholdings, indicating no reportable trading activity in this filing.

Are there any derivative positions reported for Skye Bioscience (SKYE) CFO on this Form 3?

No derivative positions are reported. The derivative summary is empty and the transaction summary lists zero derivative transactions, suggesting no options, warrants, or other derivatives are disclosed in this initial statement.

What does a neutral net buy/sell direction mean on the Skye Bioscience (SKYE) Form 3?

A neutral net buy/sell direction means there were no net purchases or sales reported. In this Form 3, all transaction counts are zero, so there is no net change in ownership reflected in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 08:37 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sharp John P

(Last) (First) (Middle)

1250 EL CAMINO REAL

SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/31/2026

3. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ John P Sharp	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)